Cytokinetics (CYTK): EVP Research & Development exercised options on 3,500 shares
Fady Ibraham Malik, EVP Research & Development at Cytokinetics, reported an option exercise of 3,500 shares.
- 3,500
- Shares · @ $7.80
- Traded
- Jul 7, 2026
- Filed
- Jul 7, 2026
The story around this disclosure
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
- May 14, 2026InsiderCEO sold ~$584K of CYTK shares in the open market
- May 19, 2026InsiderOfficer sold ~$265K of CYTK shares in the open market
- May 27, 2026InsiderCEO sold ~$579K of CYTK shares in the open market
- Jun 1, 2026Insider · 3 peopleInsiders: 3 sales (~$1.7M)
- Jun 9, 2026InsiderOfficer sold ~$238K of CYTK shares in the open market
- Jun 15, 2026InsiderCEO sold ~$528K of CYTK shares in the open market
- Jun 23, 2026InsiderOfficer sold ~$278K of CYTK shares in the open market
- Jun 24, 2026InsiderCFO sold ~$3.19M of CYTK shares in the open market
- Jun 29, 2026InsiderCFO sold ~$266K of CYTK shares in the open market
- Jun 30, 2026CongressDisclosed purchase of CYTK — reported range $1,001 - $15,000
- Jul 1, 2026Insider · 3 peopleInsiders: 3 sales (~$2.0M)
- Jul 7, 2026InsiderOfficer sold ~$303K of CYTK shares in the open market
What came next
- Jul 13, 2026Insider · 1 personInsiders: 2 sales (~$615K)
- Jul 21, 2026InsiderOfficer sold ~$282K of CYTK shares in the open market
- Jul 27, 2026InsiderCEO sold ~$607K of CYTK shares in the open market
- Jul 30, 2026InsiderOfficer sold ~$1.12M of CYTK shares in the open market
- Aug 6, 2026Company filing · Form 8-K · ResultsReported its results
- Aug 10, 2026InsiderCEO sold ~$576K of CYTK shares in the open market
- Aug 18, 2026InsiderOfficer sold ~$265K of CYTK shares in the open market
- Aug 31, 2026Insider · 2 peopleInsiders: 2 sales (~$1.2M)
- Sep 1, 2026InsiderDirector sold ~$357K of CYTK shares in the open market
- Sep 8, 2026InsiderOfficer sold ~$264K of CYTK shares in the open market
- Sep 11, 2026InsiderDirector sold ~$75K of CYTK shares in the open market
- Sep 14, 2026InsiderCEO sold ~$551K of CYTK shares in the open market
- Sep 15, 2026Insider · 2 peopleInsiders: 2 sales (~$6.9M)
- Sep 22, 2026InsiderOfficer sold ~$239K of CYTK shares in the open market
- Sep 28, 2026InsiderCEO sold ~$491K of CYTK shares in the open market
- Sep 29, 2026CongressDisclosed purchase of CYTK — reported range $1,001 - $15,000
- Oct 6, 2026InsiderOfficer sold ~$215K of CYTK shares in the open market
- Oct 12, 2026InsiderCEO sold ~$472K of CYTK shares in the open market
- Oct 20, 2026InsiderOfficer sold ~$224K of CYTK shares in the open market
- Nov 2, 2026InsiderCEO sold ~$471K of CYTK shares in the open market
How to read SEC Form 4
Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.
Full guide: What is an SEC Form 4?
What else is on file for Cytokinetics
For Cytokinetics, OQRO holds 26 insider filings (SEC Form 4 or Form 144) and 1 Congress trade report dated in the last 90 days.
These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its CYTK page.
Other recent filings by Fady Ibraham Malik, EVP Research & Development
- SEC Form 4 at Cytokinetics (CYTK)Nov 18, 2026
- SEC Form 4 at Cytokinetics (CYTK)Nov 18, 2026
- SEC Form 4 at Cytokinetics (CYTK)Nov 3, 2026
- SEC Form 4 at Cytokinetics (CYTK)Oct 20, 2026
- SEC Form 4 at Cytokinetics (CYTK)Oct 6, 2026
The full history of Fady Ibraham Malik, EVP Research & Development is on the profile page.
How this filing works
Explore the data
Common questions
Which Cytokinetics (CYTK) insider traded, and how much?
Fady Ibraham Malik, EVP Research & Development at Cytokinetics, reported an option exercise of 3,500 shares. At $7.80.
When did it happen, and when was it made public?
Traded: Jul 7, 2026. Filed: Jul 7, 2026.
Is the dollar amount exact?
It is the number of shares multiplied by the price the insider reported on the form. A grant, a gift or an option exercise has no market price, so those show shares only.
Where does this information come from?
From the SEC Form 4, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.
What else has been disclosed about Cytokinetics recently?
For Cytokinetics, OQRO holds 26 insider filings (SEC Form 4 or Form 144) and 1 Congress trade report dated in the last 90 days. They are listed on the CYTK page.
Does this mean CYTK stock is a buy or a sell?
No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.
Is OQRO free?
Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.
Other disclosures at Cytokinetics
- SEC Form 4Nov 19, 2026
- SEC Form 4Nov 19, 2026
- SEC Form 4Nov 19, 2026
- SEC Form 4Nov 18, 2026
- SEC Form 4Nov 18, 2026
- SEC Form 4Nov 18, 2026
Everything OQRO holds on this company is on its CYTK page.
This is one filing. OQRO holds the rest
Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.
OQRO is free for everyone. No card, no trial
OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data
